Copy of 2021 MMC Pricing FINAL
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
APA Newsletter on Philosophy and Computers, Vol. 18, No. 2 (Spring
NEWSLETTER | The American Philosophical Association Philosophy and Computers SPRING 2019 VOLUME 18 | NUMBER 2 FEATURED ARTICLE Jack Copeland and Diane Proudfoot Turing’s Mystery Machine ARTICLES Igor Aleksander Systems with “Subjective Feelings”: The Logic of Conscious Machines Magnus Johnsson Conscious Machine Perception Stefan Lorenz Sorgner Transhumanism: The Best Minds of Our Generation Are Needed for Shaping Our Future PHILOSOPHICAL CARTOON Riccardo Manzotti What and Where Are Colors? COMMITTEE NOTES Marcello Guarini Note from the Chair Peter Boltuc Note from the Editor Adam Briggle, Sky Croeser, Shannon Vallor, D. E. Wittkower A New Direction in Supporting Scholarship on Philosophy and Computers: The Journal of Sociotechnical Critique CALL FOR PAPERS VOLUME 18 | NUMBER 2 SPRING 2019 © 2019 BY THE AMERICAN PHILOSOPHICAL ASSOCIATION ISSN 2155-9708 APA NEWSLETTER ON Philosophy and Computers PETER BOLTUC, EDITOR VOLUME 18 | NUMBER 2 | SPRING 2019 Polanyi’s? A machine that—although “quite a simple” one— FEATURED ARTICLE thwarted attempts to analyze it? Turing’s Mystery Machine A “SIMPLE MACHINE” Turing again mentioned a simple machine with an Jack Copeland and Diane Proudfoot undiscoverable program in his 1950 article “Computing UNIVERSITY OF CANTERBURY, CHRISTCHURCH, NZ Machinery and Intelligence” (published in Mind). He was arguing against the proposition that “given a discrete- state machine it should certainly be possible to discover ABSTRACT by observation sufficient about it to predict its future This is a detective story. The starting-point is a philosophical behaviour, and this within a reasonable time, say a thousand discussion in 1949, where Alan Turing mentioned a machine years.”3 This “does not seem to be the case,” he said, and whose program, he said, would in practice be “impossible he went on to describe a counterexample: to find.” Turing used his unbreakable machine example to defeat an argument against the possibility of artificial I have set up on the Manchester computer a small intelligence. -
A Valuable Stain for Connective Tissue, Keratin and Fungi* Michel Prunieras, M.D
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector PAB: A VALUABLE STAIN FOR CONNECTIVE TISSUE, KERATIN AND FUNGI* MICHEL PRUNIERAS, M.D. Since the papers by Steedman (1), Lison (2)tion. Most of the blocks were freshly prepared and Mowry (3), the use of Alcian Blue stain hasbut some were as old as 30 years. undergone considerable change. The PAB stain (routine) runs as follow: As pointed out by Pearse (4), staining with Alcian Blue is increased when acidic groups are Deparafflo and bring sections to water. introduced by sulfation or by oxidation, due Oxidize in Permanganate for 10 minutes (2.5% to the salt linkage of the dye with acidic groups.MnO4K: 100 cc.; 5% S04112: 100 cc.; distilled water: 700 cc.). The specificity of the stain might also be im- Bleach in 2% oxalic acid, 30 seconds. proved by lowering the pH of the staining bath, Wash in running water and rinse in distilled thus making Alcian Blue staining specific forwater. strong acidic groups, as shown by Adams and Stain ooe slide 30 minutes in 0.1% Alcian Blue Sloper (5). Different oxidative procedures,8GX (Imperial Chemical Industries) in 3% acetic followed by Alcian Blue stain at various pHacid (pH 2.7, 3.0) and one other slide 10 minutes have been already described in the literature:in 1% Alcian Blue in 10% sulphuric acid (pH 0.2, 0.4). A third slide might be stained 1 minute in performie acid (Adams and Sloper, 5), per-1% Alcian Blue in distilled water. -
Product Catalog POLICIES Ordering Options Payment Methods
Product Catalog POLICIES Ordering Options Payment Methods Three Easy Ways To Order Payment Portal and ACH Visit www.sunsethcs.com/paymentportal to pay online with Phone ACH or credit card. (877) 5-SUNSET (877-578-6738) Our customer service professionals are here to assist you Net 30-Day Payment Terms M-F 8:00 AM – 5:00 PM Central Time. For qualified companies. A 1.5% monthly finance charge will be assessed on all past due invoices. Fax 312-997-9985 — Accepted 24 hours a day. COD For non-qualified companies. Email [email protected] Credit Card We accept all major credit cards. A processing fee may apply. After 10 days of invoice date, a surcharge of 2.5% will be applied. Shipping Customer Service Drop shipping available — ask your sales rep Returns about sending your order to multiple locations. Call us for a return authorization number. There is no restocking charge on orders returned within 20 days of UPS invoice. Orders returned after 20 days may be assessed a Whenever possible, orders ship via UPS. If another carrier restocking fee of 15%. No returns after 90 days. is desired, please contact your sales rep. (877) 5-SUNSET (877-578-6738) All orders are packed in the smallest boxes available and Central Distribution Center Western Distribution Center combined with other products on the order to reduce Sunset Healthcare Solutions Sunset Healthcare Solutions shipping costs. 279 Madsen Dr Ste 101 2450 Statham Blvd Bloomingdale, IL 60108 Oxnard, CA 93033 All products ship prepaid and are added to the invoice. Problems All products ship from Bloomingdale, IL or Oxnard, CA. -
Absorbable Surgical Gut Suture
Food and Drug Administration, HHS § 878.4840 § 878.4800 Manual surgical instrument in subpart E of part 807 of this chapter, for general use. subject to the limitations in § 878.9. (a) Identification. A manual surgical [53 FR 23872, June 24, 1988, as amended at 61 instrument for general use is a non- FR 1123, Jan. 16, 1996; 66 FR 38803, July 25, powered, hand-held, or hand-manipu- 2001] lated device, either reusable or dispos- able, intended to be used in various § 878.4820 Surgical instrument motors general surgical procedures. The device and accessories/attachments. includes the applicator, clip applier, bi- (a) Identification. Surgical instrument opsy brush, manual dermabrasion motors and accessories are AC-pow- brush, scrub brush, cannula, ligature ered, battery-powered, or air-powered carrier, chisel, clamp, contractor, cu- devices intended for use during surgical rette, cutter, dissector, elevator, skin procedures to provide power to operate graft expander, file, forceps, gouge, in- various accessories or attachments to strument guide, needle guide, hammer, cut hard tissue or bone and soft tissue. hemostat, amputation hook, ligature Accessories or attachments may in- passing and knot-tying instrument, clude a bur, chisel (osteotome), knife, blood lancet, mallet, disposable dermabrasion brush, dermatome, drill or reusable aspiration and injection bit, hammerhead, pin driver, and saw needle, disposable or reusable suturing needle, osteotome, pliers, rasp, re- blade. tainer, retractor, saw, scalpel blade, (b) Classification. Class I (general con- scalpel handle, one-piece scalpel, snare, trols). The device is exempt from the spatula, stapler, disposable or reusable premarket notification procedures in stripper, stylet, suturing apparatus for subpart E of part 807 of this chapter the stomach and intestine, measuring subject to § 878.9. -
Mucin Histochemistry in Tumours of Colon, Ovaries and Lung
ytology & f C H i o s l t a o n l o r g u y o Ali et al., J Cytol Histol 2012, 3:7 J Journal of Cytology & Histology DOI: 10.4172/2157-7099.1000163 ISSN: 2157-7099 ReviewResearch Article Article OpenOpen Access Access Mucin Histochemistry in Tumours of Colon, Ovaries and Lung Usman Ali*, Nagi AH, Nadia Naseem and Ehsan Ullah Department of Morbid Anatomy and Histopathology, University of Health Sciences, Lahore, Pakistan Abstract Introduction: Mucins implicated in cancers of various organs. The apical epithelial surfaces of mammalian respiratory, gastrointestinal, and reproductive tracts are coated by mucus, a mixture of water, ions, glycoproteins, proteins, and lipids. The purpose of this study was to confirm the presence of mucin production using Haematoxylin and Eosin (H&E) stain as the gold standard and to describe the types of mucins produced in tumors of lung, colon and ovaries using various types of histochemical techniques. Methods: The resection specimens and biopsies from tumours of colon (n=16), ovaries (n=13) and lung (n=5) were included and stained with H&E to determin the histological diagnosis for selecting tissues with mucin production. Slides were stained with PAS, Alcian blue, High iron diamine-Alcian blue, Meyer’s mucicarmine and Alcian blue-PAS to demonstrate the mucin production and to identify types of mucins. Results: In the present study we observed predominance of acid mucins over neutral mucins. In addition in these cases we observed sulphomucin predominating over sialomucin. Conclusion: Mucin histochemistry can effectively determine the types of mucins. Keywords: Haematoxylin and Eosin; Periodic acid schiff; High iron Materials and Methods diamine; Alcian blue Paraffin embedded sections were prepared using automatic tissue Introduction processor, followed by preparation of paraffin block using our embedding station. -
Oral and Maxillofacial Surgery
ORAL AND MAXILLOFACIAL SURGERY 3rd EDITION 2/2012 US Chapter Pages 1 BASIC SETS OMFS-SET 1-36 TELESCOPES AND INSTRUMENTS FOR FRAKT 37-54 2 ENDOSCOPIC FRACTURE TREATMENT TELESCOPES AND INSTRUMENTS FOR TMJ 55-60 3 ARTHROSCOPY OF TEMPOROMANDIBULAR JOINT TELESCOPES AND INSTRUMENTS FOR DENT 61-80 4 MAXILLARY ENDOSCOPY TELESCOPES AND INSTRUMENTS DENT-K 81-120 5 FOR DENTAL SURGERY TELESCOPES AND INSTRUMENTS SIAL 121-134 6 FOR SIALENDOSCOPY 7 FLEXIBLE ENDOSCOPES FL-E 135-142 8 HOSPITAL SUPPLIES HS 143-240 9 INSTRUMENTS FOR RHINOLOGY AND RHINOPLASTY N 241-298 10 BIPOLAR AND UNIPOLAR COAGULATION COA 299-312 11 HEADMIRRORS – HEADLIGHTS OMFS-J 313-324 12 AUTOFLUORESCENCE AF-INTRO, AF 325-342 13 HOLDING SYSTEMS HT 343-356 VISUALIZATION SYSTEMS OMFS-MICRO, OMFS-VITOM 357-378 14 FOR MICROSURGERY OMFS-UNITS-INTRO, UNITS AND ACCESSORIES U 1-54 15 OMFS-UNITS COMPONENTS OMFS-SP SP 1-58 16 SPARE PARTS KARL STORZ OR1 NEO™, TELEPRESENCE 17 HYGIENE, ENDOPROTECT1 ORAL AND MAXILLOFACIAL SURGERY 3rd EDITION 2/2012 US Important information for U.S. customers Note: Certain devices and references made herein to specific indications of use may have not received clearance or ap- proval by the United States Food and Drug Administration. Practitioners in the United States should first consult with their local KARL STORZ representative in order to ascertain product availability and specific labeling claims. Federal (USA) law restricts certain devices referenced herein to sale, distribution, and use by, or on the order of a physician, dentist, veterinarian, or other practitioner licensed by the law of the State in which she/he practices to use or order the use of the device. -
Oxymask™ Empower Best Practice
OxyMask™ Empower Best Practice. Safer Care. Exceptional Experience. Clinical Evidence Summary Executive Summary OxyMask is a solution for safer, more efficient oxygen delivery. It is an all-in-one replacement for other oxygen delivery modalities, such as the venturi mask and non-rebreather mask. The unique OxyMask technology helps enhance patient experience, increase efficiency, and reduce costs. Introduction: Enhance Patient Experience In an ever-competitive healthcare market, patient experience is at the forefront of advances in healthcare. Patients treated with oxygen therapy may feel they are trapped or helpless.1 Patient-centered solutions are increasingly recommended in policy and research.2 OxyMask brings patient-centered care to fruition through its design and dependability. Patient-centered design OxyMask utilizes a light-weight, open design that: • Sits lightly on the face • Allows unrestricted communication • Allows for oral medication delivery • May reduce the feeling of claustrophobia Dependability OxyMask is clinically proven to deliver more oxygen at lower flow rates compared to traditional delivery methods.3 Additionally, laboratory testing suggests that OxyMask reduces the risk of carbon dioxide rebreathing when compared to non-rebreather masks.4,5 OxyMask™ OxyMask Delivers Oxygen More Efficiently OxyMask May Reduce the Risk of Carbon Than a Venturi Mask3 Dioxide Rebreathing Compared to a Beecroft JM, Hanly PJ. Comparison of the OxyMask and Venturi mask in the Non-Rebreather Mask4 delivery of supplemental oxygen: Pilot study in oxygen-dependent patients. Can Respir J. 2006;13(5):247-252. Lamb K, Piper D. Southmedic OxyMaskTM compared with the Hudson RCI® Non-Rebreather Mask™: Safety and performance comparison. Can J Resp Ther. -
CPT Code Description Charge Amount 83498 17-Alpha
CPT Code Description Charge Amount 83498 17-alpha-Hydroxyprogester 308.41 83497 5-HIAA, SO 125.99 83516 A MYELOPEROX (MPO) AB QL 74.1 86021 AB ID LEUKOCYTE AB/SO 610.25 86022 AB ID, PLATELET ABS;SRA U 1318 86720 AB LEPTOSPIRA/SO 166.12 86850 AB SCREEN (IDC) 207.83 86850 AB SCREEN RBC EA SRM TECH 195.25 86793 AB, YERSINIA/SO 149 74018 ABDOMEN 1 VIEW 348.75 74018 ABDOMEN 1 VIEW PORTABLE 321.36 74022 ABDOMEN ACUTE COMP WSGL V 398.36 74019 ABDOMEN COMPLETE 398.36 74018 ABDOMEN SGL ANTEROPOSTERI 475.8 49083 ABDOMINAL PARACENTESIS W/ 1216.89 86870 ABID,WNJ 294.85 ABLATOR APOLLORF XL90 ASP 877.8 86900 ABO BLOOD TYPE 370 86900 ABO,BBSO 176.5 73050 AC JOINTS W/WO WEIGHTS BI 297.94 ACCUGRID RADIOGRAPH BREAS 121.36 82164 ACE, CSF SO 144.38 83519 ACHR BIND AB QT,RIA/SO MA 258 83519 ACHR BIND QNT MGP/SO 181.37 83519 ACHR BLOC QNT MGP/SO 181.37 83519 ACHR GANGL NEUR AB,RIA/SO 258 83519 ACHR MOD QNT MGP/SO 201.16 87116 ACID FAST CULTURE SO 227.33 83519 ACR BLOCKING QNT SO 181.37 83519 ACR RECEPTOR QNT SO 108.61 82024 ACTH,SO 459.3 86602 ACTINOMYCES AB/SO 64 85347 ACTIVATED CLOTTING TIME 126.93 85307 Activated Protein C Resis 216.04 97535GO ACTIVITY DAILY LIVING 15 265.91 78278 ACUTE GI BLOOD LOSS IMAGI 1326.15 82017 ACYLCARNITINES; QUANT, EA 574 85397 ADAMSTS 13 ACTIVITY/SO 796.62 ADAPTER CATH LUER 8.69 ADAPTER CONFIDENCE CEMENT 743.66 ADAPTER DLP PERFUS Y W/6 47.54 ADAPTER FIBEROPTIC SWIVEL 73.16 ADAPTER LUER LOC SHORT 3/ 2.2 ADAPTER LUER TO COLDER 15.29 ADAPTER MALE-MALE 4.57 C1776 ADAPTER PFC SIGMA FEMORAL 8474.76 ADAPTER PLUG MALE CLAVE 5.02 ADAPTER PRODIGY EXTENSION 2340 ADAPTER UROSTOMY DRAIN TU 9.09 ADAPTER VERSO AIRWAY ADUL 33.51 82952 ADDL GLUCOSE > 3 SPEC 136.24 87260 ADENOV/ RSPFAC / SO 141.75 ADHESIVE DEMABOND .07 PEN 193.48 ADHESIVE DEMABOND .07 PEN 193.48 ADHESIVE DERMABOND PEN 0. -
Hospitals for War-Wounded
hospitals_war_cover_april2003 9.6.2005 13:47 Page 1 ICRC HOSPITALS FOR WAR-WOUNDED HOSPITALS FORHOSPITALS WAR-WOUNDED This book is intended for anyone who is faced A practical guide for setting up with the task of setting up or running a hospital and running a surgical hospital which admits war-wounded. It is a practical guide in an area of armed conflict based on the experience of four nurses who have managed independent hospitals set up by the International Committee of the Red Cross. It addresses specific problems associated with setting up a hospital in a difficult and potentially dangerous environment. It provides a framework for the administration of such a hospital. It also describes a system for managing the patients from admission to discharge and includes guidelines on how to manage an influx of wounded. These guidelines represent a realistic and achievable standard of care whatever the circumstances. A practical guide 0714/002 05/2005 1000 HOSPITALS FOR WAR-WOUNDED International Committee of the Red Cross 19 Avenue de la Paix 1202 Geneva, Switzerland T +41 22 734 6001 F +41 22 733 2057 E-mail: [email protected] www.icrc.org # ICRC, April 2005, revised and updated edition This book is dedicated to the memory of Jo´n Karlsson (died in Afghanistan, 22 April 1992) Fernanda Calado Hans Elkerbout Ingebjørg Foss Nancy Malloy Gunnhild Myklebust Sheryl Thayer (died in Chechnya, 17 December 1996) HOSPITALS FOR WAR-WOUNDED A practical guide for setting up and running a surgical hospital in an area of armed conflict Jenny Hayward-Karlsson Sue Jeffery Ann Kerr Holger Schmidt INTERNATIONAL COMMITTEE OF THE RED CROSS ISBN 2-88145-094-6 # International Committee of the Red Cross, Geneva, 1998 WEB address: http://www.icrc.org CONTENTS vii CONTENTS FOREWORD ............................................ -
How to Deliver Aerosolized Medications Through High Flow Nasal Cannula Safely and Effectively in the Era of COVID-19 and Beyond: a Narrative Review
NARRATIVE REVIEW How to deliver aerosolized medications through high flow nasal cannula safely and effectively in the era of COVID-19 and beyond: A narrative review Arzu Ari, PhD, RRT, PT, CPFT, FAARC, FCCP1, Gerald B. Moody, BSRC, RRT-NPS2 A Ari, GB Moody. How to deliver aerosolized medications through high flow nasal cannula safely and effectively in the era of COVID-19 and beyond: A narrative review. Can J Respir Ther 2021;57:22–25. doi: 10.29390/cjrt-2020-041. Background: The treatments of COVID-19 involve some degree of uncertainty. Current evidence also shows mixed findings with regards to bioaerosol dispersion and airborne transmission of COVID-19 during high flow nasal cannula (HFNC) therapy. While coping with this global pandemic created hot debates on the use of HFNC, it is important to bring detached opinions and current evidence to the attention of health care professionals (HCPs) who may need to use HFNC in patients with COVID-19. Aim: The purpose of this paper is to provide a framework on the selection, placement, and use of nebulizers as well as HFNC prongs, gas flow, and delivery technique via HFNC to help clinicians deliver aerosolized medications through HFNC safely and effectively in the era of COVID-19 and beyond. Methods: We searched PubMed, Medline, CINAHL, and Science Direct to identify studies on aerosol drug delivery through HFNC using the following keywords: (“aerosols,” OR “nebulizers”) AND (“high flow nasal cannula” OR “high flow oxygen therapy” OR “HFNC”) AND (“COVID-19,” OR “SARS- CoV-2”). Twenty-eight articles including in vitro studies, randomized clinical trials, scintigraphy studies, review articles, prospective and retrospective research were included in this review. -
Oxygen Therapy
Copyright EMAP Publishing 2015 This article is not for distribution Keywords: Breathing/Oxygen/ Nursing Practice Oxygen therapy/Respiratory care Practice educator ●This article has been double-blind Respiratory care peer reviewed Oxygen therapy can be lifesaving but nurses must know how it works, when to use it, and how to correctly assess and evaluate a patient’s treatment Practical procedures: oxygen therapy In this article... 5 key The rationale for using oxygen therapy in acute illness points Hypoxia is an Available oxygen delivery devices and indications for use 1indication that The need for monitoring while administering oxygen therapy oxygen therapy should be started If blood Author Sandra Olive, respiratory nurse hypoxaemia (low blood oxygen levels); 2oxygen levels specialist, Norfolk and Norwich University » Prescribing a target oxygen are not low, oxygen Hospitals Foundation Trust. saturation range to guide will not treat Abstract Olive S (2016) Practical therapeutic treatment. breathlessness procedures: oxygen therapy. Oxygen does not treat breathlessness in A target Nursing Times; 112: 1/2, 12-14. the absence of hypoxaemia (O’Driscoll et 3oxygen Knowing when to start patients on oxygen al, 2008). saturation range therapy can save lives, but ongoing In an emergency situation, immediate should be assessment and evaluation must be assessment of airway patency, breathing prescribed to carried out to ensure the treatment is safe and circulation is essential, and in critical guide therapy and effective. This article outlines when illness such as peri-arrest, high-concentra- A lower target oxygen therapy should be used and the tion oxygen should be commenced via res- 4saturation procedures to follow. -
A Guide to Aerosol Delivery Devices for Respiratory Therapists 4Th Edition
A Guide To Aerosol Delivery Devices for Respiratory Therapists 4th Edition Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Dave Burnett, PhD, RRT, AE-C Shawna Strickland, PhD, RRT-NPS, RRT-ACCS, AE-C, FAARC Timothy R. Myers, MBA, RRT-NPS, FAARC Platinum Sponsor Copyright ©2017 by the American Association for Respiratory Care A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th Edition Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Dave Burnett, PhD, RRT, AE-C Shawna Strickland, PhD, RRT-NPS, RRT-ACCS, AE-C, FAARC Timothy R. Myers, MBA, RRT-NPS, FAARC With a Foreword by Timothy R. Myers, MBA, RRT-NPS, FAARC Chief Business Officer American Association for Respiratory Care DISCLOSURE Douglas S. Gardenhire, EdD, RRT-NPS, FAARC has served as a consultant for the following companies: Westmed, Inc. and Boehringer Ingelheim. Produced by the American Association for Respiratory Care 2 A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th Edition American Association for Respiratory Care, © 2017 Foreward Aerosol therapy is considered to be one of the corner- any) benefit from their prescribed metered-dose inhalers, stones of respiratory therapy that exemplifies the nuances dry-powder inhalers, and nebulizers simply because they are of both the art and science of 21st century medicine. As not adequately trained or evaluated on their proper use. respiratory therapists are the only health care providers The combination of the right medication and the most who receive extensive formal education and who are tested optimal delivery device with the patient’s cognitive and for competency in aerosol therapy, the ability to manage physical abilities is the critical juncture where science inter- patients with both acute and chronic respiratory disease as sects with art.